Garner Thomas's most recent trade in Acadia Pharmaceuticals Inc was a trade of 97,947 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 6, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acadia Pharma Inc | Thomas A. Garner | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2026 | 97,947 | 97,947 | - | - | Stock Option (Right to Buy) | |
| Acadia Pharma Inc | Thomas A. Garner | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2026 | 28,493 | 28,493 | - | - | Restricted Stock Units | |
| Lexicon Pharma Inc | Garner Thomas | SVP, Chief Commercial Officer | 08 Feb 2024 | 227,130 | 227,130 | - | - | Restricted Stock Units | ||
| Lexicon Pharma Inc | Garner Thomas | SVP, Chief Commercial Officer | 08 Feb 2024 | 227,130 | 227,130 | - | - | Stock Option (Right to Buy) |